Unfortunately, the patient was not eligible for ASCT because of severe bortezomib‐ and thalidomide‐induced neuropathy and JAK2‐mutated myeloproliferative neoplasm with marked splenomegaly. This evidence concerns the gene JAK2 and Splenomegaly.